Steven Snapinn

15.1k total citations · 2 hit papers
110 papers, 10.6k citations indexed

About

Steven Snapinn is a scholar working on Statistics and Probability, Cardiology and Cardiovascular Medicine and Economics and Econometrics. According to data from OpenAlex, Steven Snapinn has authored 110 papers receiving a total of 10.6k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Statistics and Probability, 42 papers in Cardiology and Cardiovascular Medicine and 24 papers in Economics and Econometrics. Recurrent topics in Steven Snapinn's work include Statistical Methods in Clinical Trials (41 papers), Health Systems, Economic Evaluations, Quality of Life (21 papers) and Blood Pressure and Hypertension Studies (19 papers). Steven Snapinn is often cited by papers focused on Statistical Methods in Clinical Trials (41 papers), Health Systems, Economic Evaluations, Quality of Life (21 papers) and Blood Pressure and Hypertension Studies (19 papers). Steven Snapinn collaborates with scholars based in United States, Sweden and Denmark. Steven Snapinn's co-authors include Shahnaz Shahinfar, Barry M. Brenner, Dick de Zeeuw, William F. Keane, William E. Mitch, Mark E. Cooper, Giuseppe Remuzzi, Hans‐Henrik Parving, Qi Jiang and Jonathan M. Edelman and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Steven Snapinn

107 papers receiving 10.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

2001 5.4k citations Steven Snapinn et al. profile →
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

2002 1.1k citations Lars Lindholm, Hans Ibsen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven Snapinn United States	33	6.2k	3.7k	2.9k	1.4k	939	110	10.6k
Shahnaz Shahinfar United States	31	6.1k 1.0×	4.3k 1.2×	5.2k 1.8×	900 0.7×	1.2k 1.3×	54	11.0k
Raymond P. Bain United States	33	3.2k 0.5×	3.0k 0.8×	2.3k 0.8×	1.1k 0.8×	792 0.8×	58	8.8k
Janice Pogue Canada	42	14.7k 2.4×	2.5k 0.7×	680 0.2×	2.0k 1.4×	949 1.0×	74	19.3k
Richard H. Grimm United States	52	6.3k 1.0×	6.8k 1.8×	952 0.3×	2.5k 1.8×	714 0.8×	135	15.1k
Hans‐Henrik Parving Denmark	53	7.8k 1.2×	8.3k 2.2×	6.1k 2.1×	2.1k 1.6×	1.4k 1.5×	122	17.7k
Eric L. Michelson United States	58	17.7k 2.8×	3.2k 0.9×	903 0.3×	2.0k 1.5×	2.3k 2.4×	192	20.9k
Stephen E. Kimmel United States	55	4.0k 0.6×	959 0.3×	895 0.3×	1.4k 1.1×	1.4k 1.5×	155	10.0k
Lawrence G. Hunsicker United States	48	7.6k 1.2×	5.4k 1.4×	8.5k 2.9×	3.0k 2.2×	2.4k 2.5×	134	19.0k
K. Borch‐Johnsen Denmark	59	3.0k 0.5×	5.5k 1.5×	2.2k 0.8×	1.7k 1.3×	601 0.6×	176	12.5k
Andrew S. Narva United States	27	4.3k 0.7×	2.3k 0.6×	2.2k 0.8×	1.1k 0.8×	672 0.7×	60	9.4k

Countries citing papers authored by Steven Snapinn

Since Specialization

Citations

This map shows the geographic impact of Steven Snapinn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Snapinn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Snapinn more than expected).

Fields of papers citing papers by Steven Snapinn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Snapinn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Snapinn. The network helps show where Steven Snapinn may publish in the future.

Co-authorship network of co-authors of Steven Snapinn

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Snapinn. A scholar is included among the top collaborators of Steven Snapinn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Snapinn. Steven Snapinn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Snapinn, Steven, Qi Jiang, & Chunlei Ke. (2022). Treatment effect measures under nonproportional hazards. Pharmaceutical Statistics. 22(1). 181–193. 7 indexed citations

Singh, Ajay, Finnian R. Mc Causland, Brian Claggett, et al.. (2022). Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents—post hoc analyses of the ASCEND-ND and ASCEND-D trials. Nephrology Dialysis Transplantation. 38(8). 1890–1897. 8 indexed citations

Snapinn, Steven, et al.. (2021). Comparison of Sample Size Requirements of Randomized and Historically Controlled Trials Based on Calibrated Error Rates. Statistics in Biopharmaceutical Research. 15(1). 69–73.

Lipton, Richard B., David W. Dodick, Jessica Ailani, et al.. (2020). Patient-Identified Most Bothersome Symptom in Patients with Chronic Migraine: An Analysis of PROMISE-2 (541). Neurology. 94(15_supplement). 1 indexed citations

Ke, Chunlei, Jianming Wang, Charlie Zhang, Qi Jiang, & Steven Snapinn. (2017). On Errors in Stratified Randomization. Statistics in Biopharmaceutical Research. 9(2). 225–233. 4 indexed citations

Ma, Haijun, Chunlei Ke, Qi Jiang, & Steven Snapinn. (2015). Statistical Considerations on the Evaluation of Imbalances of Adverse Events in Randomized Clinical Trials. Therapeutic Innovation & Regulatory Science. 49(6). 957–965. 11 indexed citations

Snapinn, Steven & Qi Jiang. (2011). On the clinical meaningfulness of a treatment's effect on a time‐to‐event variable. Statistics in Medicine. 30(19). 2341–2348. 12 indexed citations

Spector, Reynold & Steven Snapinn. (2011). Statins for Secondary Prevention of Cardiovascular Disease: The Right Dose. Pharmacology. 87(1-2). 63–69. 22 indexed citations

Snapinn, Steven & Qi Jiang. (2007). Preservation of effect and the regulatory approval of new treatments on the basis of non‐inferiority trials. Statistics in Medicine. 27(3). 382–391. 34 indexed citations

10.

Dickstein, Kenneth, et al.. (2005). The Impact of Morbid Events on Survival Following Hospitalization for Complicated Myocardial Infarction. European Journal of Heart Failure. 8(1). 74–80. 10 indexed citations

11.

Jiang, Qi, Steven Snapinn, & Boris Iglewicz. (2005). Accounting for informative non-compliance with a bivariate exponential model in the design of endpoint trials. Pharmaceutical Statistics. 4(3). 173–186. 1 indexed citations

12.

Jiang, Qi, Steven Snapinn, & Boris Iglewicz. (2004). Calculation of Sample Size in Survival Trials: The Impact of Informative Noncompliance. Biometrics. 60(3). 800–806. 12 indexed citations

13.

Kizer, Jorge R., Björn Dahlöf, Sverre E. Kjeldsen, et al.. (2004). Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol. Hypertension. 45(1). 46–52. 72 indexed citations

14.

Servoss, Stephen J., Ying Wan, Steven Snapinn, et al.. (2004). Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. The American Journal of Cardiology. 93(7). 843–847. 22 indexed citations

15.

Devereux, Richard B., Kristian Wachtell, Eva Gerdts, et al.. (2003). Prognostic significance of left ventricular hypertrophy during treatment of hypertension: The LIFE study. Journal of the American College of Cardiology. 41(6). 228–228. 2 indexed citations

16.

Williams, George W., Robert L. Davis, Albert J. Getson, et al.. (1993). Monitoring of clinical trials and interim analyses from a drug Sponsor's point of view. Statistics in Medicine. 12(5-6). 481–492. 13 indexed citations

17.

Helve, Eero, Matti J. Tikkanen, A Jäättelä, et al.. (1990). Switch from Gemfibrozil to Lovastatin (Mevinolin) Therapy in Patients with Primary Hypercholesterolaemia. Clinical Drug Investigation. 2(S2). 40–47. 5 indexed citations

18.

Greenspon, Arnold J., et al.. (1989). Comparison of intravenous tocainide with intravenous lidocaine for treating ventricular arrhythmias. 10(1). 55–59. 1 indexed citations

19.

Stone, Charles K., Barry F. Uretsky, Thomas J. Linnemeier, et al.. (1989). Hemodynamic effects of lisinopril after long-term administration in congestive heart failure. The American Journal of Cardiology. 63(9). 567–570. 7 indexed citations

20.

Shachtman, Richard H., et al.. (1986). A method for constructing case-mix indexes, with application to hospital length of stay.. PubMed. 20(6 Pt 1). 737–62. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact